Inmunopatología
Actividades del grupo
Células natural killer (NK) y cáncer: a la búsqueda de nuevos métodos para incrementar la eficacia de la inmunoterapia tumoral
Las células NK son una subpoblación de linfocitos que desempeñan un papel vital en la respuesta inmune frente al desarrollo de tumores e infecciones virales. La lisis de células infectadas por virus y células transformadas está regulada por señales que se generan desde receptores activadores e inhibidores en la superficie de las células NK. Además de su capacidad citotóxica, la activación de células NK lleva a la liberación de citocinas, tales como interferón (IFN)-?, factor de necrosis tumoral (TNF) y factor estimulante de colonias de granulocitos macrófagos (GM-CSF). La liberación de estas citocinas es particularmente importante para el desarrollo de la respuesta inmune adaptativa, la reconstitución celular después del trasplante de médula haploidéntico, y en el control del crecimiento tumoral. Numerosos estudios in vitro han demostrado que las células NK de sangre periférica ejercen una potente actividad citotóxica frente a diversas líneas de células tumorales, la cual aumenta significativamente después de la activación de las células NK con ciertas citocinas tales como la interleucina (IL)-2, IL-12, IL-15, IL-18, IFN-? e IFN-?. Debido a su gran capacidad para lisar células tumorales, las células NK se han descrito como prometedores efectores en la inmunoterapia adoptiva contra el cáncer. Existen muchas ventajas en el uso de células NK como parte de la inmunoterapia.
Nuestro grupo pretende descubrir nuevas estrategias con el objetivo de modular la actividad NK para combatir el cáncer. Para ello, los objetivos que tenemos son: identificar y validar nuevas dianas terapéuticas en cáncer, identificación de las bases moleculares de células NK memoria que se caracterizan por funciones efectoras aumentadas, identificar mecanismos que incrementen la eficacia de anticuerpos terapéuticos que usan células NK en su mecanismo de acción, y generación de células NK transducidas con receptores quiméricos de antígeno.
Papel de la familia de receptores CD300 en la respuesta inmunológica
La familia de receptores CD300 reconocen fosfolípidos, tales como fosfatidilserina (PS) y fosfatidiletanolamina (PE). A través de su unión a lípidos, esta familia de receptores tiene un papel muy importante en la respuesta del huésped en condiciones patológicas severas y en procesos biológicos complejos, tales como la fagocitosis, proliferación celular y producción de citocinas. La PS se segrega, junto con la PE, a la parte interna de la membrana en las células que están en reposo. La pérdida de la asimetría de la membrana plasmática se produce durante apoptosis, injuria celular, infecciones virales y transformación maligna. Nuestro grupo está investigando como la exposición de PS y PE modula la respuesta inmunológica e inflamatoria, a través de su interacción con las moléculas CD300, durante el curso de ciertas infecciones por virus, como el VIH También estamos caracterizando la expresión de las moléculas CD300 en el neonato con el objetivo de determinar si tienen un papel relevante en la inmunodeficiencia del recién nacido.
Proyectos Financiados - Investigador Principal
Infección por el virus de la inmunodeficiencia humana (VIH): participación de la familia de receptores CD300 en la inflamación crónica y mecanismos de escape viral. Financiación: Instituto de Salud Carlos III, Ministerio de Economía y Competitividad. Número de referencia: PI13/00889. Investigador Principal: Francisco Borrego. 2014-2016.
The CD300 family of receptors in HIV infection. Financiación: Marie Curie, Career Integration Grant, European Commission. Número de referencia: CIG631674. Investigador Principal: Francisco Borrego. 2014-2018.
Papel de la familia de receptores CD300 en el Sistema Inmunológico del neonato. Financiación: SAIOTEK, Gobierno Vasco. Número de referencia: SAIO13-PE13BF005. Investigador Principal: Francisco Borrego. 2013.
Identificación y validación de nuevas dianas terapéuticas en cáncer hematológico. Financiación: Departamento de Salud, Gobierno Vasco. Número de referencia: 2013111034. Investigador Principal: Francisco Borrego. 2013-2015.
Increasing natural killer (NK) cell effector functions for the treatment of pediatric hematological cancer. Financiación: BIOEF-Fundación Vasca de Innovación e Investigación Sanitarias. Número de referencia: BIO13/CI/011. Investigador Principal: Francisco Borrego. 2015-2017.
Proyectos Financiados - Investigador Colaborador
Aplicación de la proteómica, estudios celulares y de citocinas para la identificación de los factores inmunológicos del huésped implicados en el fallo multiorgánico de pacientes con sepsis graves y síndromes hemofagocíticos. Financiación: Departamento de Salud, Gobierno Vasco. Investigadora Principal: Itziar Astigarraga. 2013-2015.
Estudio comparativo del efecto inmunomodulador de diferentes tipos de células multipotentes (CB-SC, PB-MSC y CB-MSC) sobre los diversos tipos celulares del linaje blanco sanguíneo. Financiación: SAIOTEK, Gobierno Vasco. Número de referencia: SAIO13-PE13BF006. Investigadora Principal: Cristina Eguizábal. 2013.
Proyecto: Arming human NK cells with chimeric antigen receptors (CARs) for the treatment of refractory pediatric hematological cancer. Financiación: BIOEF-Fundación Vasca de Innovación e Investigación Sanitarias. Número de referencia: BIO13/CI/009. Investigadora Principal: Cristina Eguizabal. 2015-2017.
Coordinador/a del grupo
-
Francisco Borrego Rabasco
Coordinador de grupo
francisco.borregorabasco@osakidetza.eus
847079
CV resumen
Miembros del grupo
Publicaciones del grupo
Terren I, Astarloa Pando G, Amarilla Irusta A, Borrego F. P815-based redirected degranulation assay to study human NK cell effector functions. METHOD CELL BIOL. 2023; 173: 33-48. DOI:10.1016/bs.mcb.2022.02.002.
Manini C, Provenza C, Andres L, Imaz I, Guarch R, Nunziata R, et al. Tumor-to-Tumor Metastases Involving Clear Cell Renal Cell Carcinomas: A Diagnostic Challenge for Pathologists Needing Clinical Correlation. Clin Pract. 2023; 13(1): 288-296. DOI:10.3390/clinpract13010026.
Mustafa N, Mitxelena J, Infante A, Zenarruzabeitia O, Eriz A, Iglesias Ara A, et al. E2f2 Attenuates Apoptosis of Activated T Lymphocytes and Protects from Immune-Mediated Injury through Repression of Fas and FasL. Int J Mol Sci. 2022; 23(1). DOI:10.3390/ijms23010311.
Terren I, Borrego F. Role of NK Cells in Tumor Progression. Experientia Supplementum (2012). 2022; 113: 169-187. DOI:10.1007/978-3-030-91311-3_6.
Terren I, Orrantia A, Astarloa Pando G, Amarilla Irusta A, Zenarruzabeitia O, Borrego F. Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications. Front Immunol. 2022; 13. DOI:10.3389/fimmu.2022.884648.
Gimenez Arnau AM, Jauregui I, Silvestre Salvador JF, Valero A, Ferrer M, Sastre J, et al. Consensus on the definition of disease control and response assessment in chronic urticaria. J Invest Allergol Clin Immunol. 2022; 32(4): 0-0. DOI:10.18176/jiaci.0820.
Gimenez Arnau A, Bartra J, Ferrer M, Jauregui I, Borbujo J, Figueras I, et al. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience. J Invest Allergol Clin Immunol. 2022; 32(3): 191-199. DOI:10.18176/jiaci.0661.
Gamboa P, Vicente JSD, Galan C, Jauregui I, Segurola A, Garcia Lirio E, et al. Non-immediate hypersensitivity reactions to IOMEPROL: diagnostic value of skin tests and cross reactivity with other iodinated contrast media. Allergy. 2022; 77(12): 3641-3647. DOI:10.1111/all.15433.
Naranjo J, Borrego F, Rocha JL, Salgueira M, Adoracion Martin Gomez M, Orellana C, et al. Real clinical experience after one year of treatment with tolvaptan in patients with autosomal dominant polycystic kidney disease. Front Med (Lausanne). 2022; 9. DOI:10.3389/fmed.2022.987092.
Orrantia A, Vazquez De Luis E, Astarloa Pando G, Terren I, Amarilla Irusta A, Polanco Alonso D, et al. Invivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation. iScience. 2022; 25(10): 105235-105235. DOI:10.1016/j.isci.2022.105235.
Ferrer Puga M, Silvestre Salvador JF, Bartra Tomas J, Gimenez Arnau A, Labrador Horrillo M, Miquel J, et al. Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study. Actas Dermo-Sifilogr. 2022; 113(1): 4-14. DOI:10.1016/j.ad.2021.06.014.
Ferrer Puga M, Silvestre Salvador JF, Bartra Tomas J, Gimenez Arnau A, Labrador Horrillo M, Miquel J, et al. Daily Clinical Practice in the Management of Chronic Urticaria in Spain: Results of the UCREX Study. Actas Dermo-Sifilogr. 2022; 113(1): 4-14. DOI:10.1016/j.ad.2021.06.007.
Polanco C, Uversky VN, Dayhoff GW, Huberman A, Buhse T, Marquez MF, et al. Bioinformatics-Based Characterization of Proteins Related to SARS-CoV-2 Using the Polarity Index Method (R) (PIM (R)) and Intrinsic Disorder Predis-position. Curr Proteomics. 2022; 19(1): 51-64. DOI:10.2174/1570164618666210106114606.
Polanco C, Uversky VN, Vargas Alarcon G, Buhse T, Huberman A, Marquez MF, et al. Characterization of Proteins from Putative Human DNA and RNA Viruses. Curr Proteomics. 2022; 19(1): 65-82. DOI:10.2174/1570164618666210212123850.
Zozaya N, Caballero T, Gonzalez Quevedo T, Gamboa Setien P, Angeles Gonzalez MA, Jodar R, et al. A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain. Glob Reg Health Technol Assess. 2022; 9: 14-21. DOI:10.33393/grhta.2022.2333.
Pranger CL, Singer JF, Koehler VK, Pali Schoell I, Fiocchi A, Karagiannis SN et al. New tools in basophil activation tests (BAT): PIPE-cloned human IgE, IgG1, and IgG4 antibodies specific for the major milk allergen beta-lactoglobulin (BLG). Allergologie. 2021; 44(2): 157-158
Terren I, Orrantia A, Mosteiro A, Vitalle J, Zenarruzabeitia O, Borrego F. Metabolic changes of Interleukin-12/15/18-stimulated human NK cells. Sci Rep. 2021; 11(1): 6472-6472. DOI:10.1038/s41598-021-85960-6.
Orrantia A, Terren I, Astarloa Pando G, Zenarruzabeitia O, Borrego F. Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment. Cancers (Basel). 2021; 13(7). DOI:10.3390/cancers13071589.
Zenarruzabeitia O, Astarloa Pando G, Terren I, Orrantia A, Perez Garay R, Seijas Betolaza I et al. T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19. Front Immunol. 2021; 12. DOI:10.3389/fimmu.2021.655934.
Anton MDM, Jauregui I, Galan C, de Vicente JS, Segurola A, Seras Y et al. Two cases of allergic contact dermatitis to different elements in identical ultrasound gels. Contact Dermatitis. 2021; 85(4): 477-478. DOI:10.1111/cod.13901.
Gamboa P, Sanchez de Vicente J, Galan C, Jauregui I, Segurola A, Garcia Lirio E et al. Tolerance to iopamidol in patients with confirmed allergic immediate hypersensitivity to iomeprol. J Allergy Clin Immunol-Pract. 2021; 9(5): 2101-21031. DOI:10.1016/j.jaip.2020.12.057.
Magadan S, Mikelez Alonso I, Borrego F, Gonzalez Fernandez A. Nanoparticles and trained immunity: glimpse into the future. Adv Drug Deliv Rev. 2021; 175: 113821-113821. DOI:10.1016/j.addr.2021.05.031.
Mikelez Alonso I, Magadan S, Gonzalez Fernandez A, Borrego F. Natural killer (NK) cell-based immunotherapies and the many faces of NK cell memory: A look into how nanoparticles enhance NK cell activity. Adv Drug Deliv Rev. 2021; 176: 113860-113860. DOI:10.1016/j.addr.2021.113860.
Del Amo C, Perez Valle A, Perez Garrastachu M, Jauregui I, Andollo N, Arluzea J et al. Plasma-Based Bioinks for Extrusion Bioprinting of Advanced Dressings. Biomedicines. 2021; 9(8). DOI:10.3390/biomedicines9081023.
Mustafa N, Infante A, Zenarruzabeitia O, Mitxelena J, Iglesias Ara A, Zubiaga AM. E2F2 protects activated T-lymphocytes from apoptosis through repression of Fas/FasL-dependent mechanisms. FEBS Open Bio. 2021; 11: 457-458
Orrantia A, Terrén I, Astarloa Pando G, González C, Uranga A, Mateos Mazón JJ et al. NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma. Front Immunol. 2021; 12: 748207-748207. DOI:10.3389/fimmu.2021.748207.
Bilbao A, Perez Garay R, Rius I, Irurzun A, Terren I, Orrantia A et al. Increased Frequency of CTLA-4 and PD-1 Expressing Regulatory T Cells and Basophils With an Activating Profile in Infants With Moderate-to-Severe Atopic Dermatitis Hypersensitized to Food Allergens. Front Pediatr. 2021; 9. DOI:10.3389/fped.2021.734645.
Pando GA, Zenarruzabeitia O, Terren I, Orrantia A, Garay RP, Betolaza IS et al. T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression in severe COVID-19. Eur J Immunol. 2021; 51: 267-267
Terren I, Orrantia A, Mosteiro A, Vitalle J, Pando GA, Zenarruzabeitia O et al. Metabolic changes of cytokine-induced memory-like human NK cells and glycolytic-dependence of their effector functions. Eur J Immunol. 2021; 51: 143-143
Zenarruzabeitia O, Bilbao A, Garay RP, Irurzun A, Terren I, Orrantia A et al. PD-1 expressing regulatory T cells and basophils with an activating profile in infants with moderate-to-severe atopic dermatitis hypersensitized to food antigens. Eur J Immunol. 2021; 51: 76-76
Irazabal B, de Vicente JS, Galan C, Segurola A, Seras Y, Garcia Lirio E et al. Anaphylaxis Due to Senna (Cassia angustifolia). J Invest Allergol Clin Immunol. 2021; 31(1). DOI:10.18176/jiaci.0608.
Orrantia A, Terren I, Pando GA, Gonzalez C, Uranga A, Mazon JJM et al. High frequency of mature CD57+NKG2A-NK cells associate with poor disease progression after autologous hematopoietic stem cell transplantation in multiple myeloma patients. Eur J Immunol. 2021; 51: 271-271
Sánchez de Vicente J, Gamboa P, García Lirio E, Irazabal B, Jáuregui I, Martínez MD, et al. Tolerance to cephalosporins and carbapenems in penicillin allergic patients. J Invest Allergol Clin Immunol. 2020; 30(1): 75-76. DOI:10.18176/jiaci.0463.
Benito J, Fernandez S, Gendive M, Santiago P, Perez Garay R, Arana Arri E, et al. A new clinical score to identify children at low risk for appendicitis. Am J Emerg Med. 2020; 38(3): 554-561. DOI:10.1016/j.ajem.2019.05.050.
Terrén I, Orrantia A, Mikelez Alonso I, Vitallé J, Zenarruzabeitia O, Borrego F. NK Cell-Based Immunotherapy in Renal Cell Carcinoma. Cancers (Basel). 2020; 12(2). DOI:10.3390/cancers12020316.
Vitalle J, Tarancon Diez L, Jimenez Leon MR, Terren I, Orrantia A, Roca Oporto C, et al. CD300a identifies a CD4+ memory T cell subset with a higher susceptibility to HIV-1 infection. Aids. 2020; 34(8): 1249-1252. DOI:10.1097/QAD.0000000000002544.
Vitalle J, Terren I, Orrantia A, Bilbao A, Gamboa PM, Borrego F, et al. The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils. Int J Mol Sci. 2020; 21(9). DOI:10.3390/ijms21093173.
Vitalle J, Terren I, Gamboa Urquijo L, Orrantia A, Tarancon Diez L, Genebat M, et al. Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a. Sci Rep. 2020; 10(1): 6070-6070. DOI:10.1038/s41598-020-63025-4.
Rozbesky D, Monistrol J, Jain V, Hillier J, Padilla Parra S, Jones EY. Drosophila OTK Is a Glycosaminoglycan-Binding Protein with High Conformational Flexibility. Structure. 2020; 28(5). DOI:10.1016/j.str.2020.02.008.
Rozbesky D, Verhagen MG, Karia D, Nagy GN, Alvarez L, Robinson RA, et al. Structural basis of semaphorin-plexin cis interaction. Embo J. 2020. DOI:10.15252/embj.2019102926.
Coomer CA, Carlon Andres I, Iliopoulou M, Dustin ML, Compeer EB, Compton AA, et al. Single-cell glycolytic activity regulates membrane tension and HIV-1 fusion. PLoS Pathog. 2020; 16(2). DOI:10.1371/journal.ppat.1008359; 10.1371/journal.ppat.1008359.r001; 10.1371/journal.ppat.1008359.r002; 10.1371/journal.ppat.1008359.r003; 10.1371/journal.ppat.1008359.r004; 10.1371/journal.ppat.1008359.r005.
Carlon Andres I, Padilla Parra S. Quantitative FRET-FLIM-BlaM to Assess the Extent of HIV-1 Fusion in Live Cells. Viruses. 2020; 12(2). DOI:10.3390/v12020206.
Martinez Anton MD, Galan Gimeno C, Sanchez de Vicente J, Jauregui Presa I, Gamboa Setien PM. Etoricoxib-Induced Fixed Drug Eruption: Report Of Seven Cases. Contact Dermatitis. 2020; 84(3): 192-195. DOI:10.1111/cod.13659.
Orrantia A, Terrén I, Izquierdo Lafuente A, Alonso Cabrera JA, Sandá V, Vitallé J, et al. A NKp80-Based Identification Strategy Reveals that CD56 neg NK Cells Are Not Completely Dysfunctional in Health and Disease. iScience. 2020; 23(7): 101298-101298. DOI:10.1016/j.isci.2020.101298.
Cardenas Fernandez MC, Perez Surribas D, Perez Garay R, Jimenez J, Gella Concustell A, Zapico Muniz E, et al. Vertical cutoff methods in serum protein electrophoresis for the measurement of monoclonal protein concentrations: Which is best?. Clin Chim Acta. 2020; 510: 573-580. DOI:10.1016/j.cca.2020.07.051.
Pranger CL, Fazekas Singer J, Kohler VK, Pali Scholl I, Fiocchi A, Karagiannis SN, et al. PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance. Allergy. 2020; 76(5): 1553-1556. DOI:10.1111/all.14604.
Zenarruzabeitia O, Vitalle J, Terren I, Orrantia A, Bilbao A, Jauregui I, et al. Immunological changes, including CD300 molecules expression, during allergen desensitization immunotherapy. Allergy. 2020; 75: 126-126
Pranger CL, Singer JF, Kohler VK, Pali Scholl I, Fiocchi A, Zenarruzabeitia O, et al. PIPE-cloned human IgG4 antibodies inhibit activation of human basophils sensitized with IgE antibodies specific for the major milk allergen beta-lactoglobulin in basophil activation tests (BAT). Allergy. 2020; 75: 242-243
Terren I, Orrantia A, Vitalle J, Astarloa Pando G, Zenarruzabeitia O, Borrego F. Modulating NK cell metabolism for cancer immunotherapy. Seminars In Hematology. 2020; 57(4): 213-224. DOI:10.1053/j.seminhematol.2020.10.003.
Orrantia A, Terren I, Vitalle J, Astarloa Pando G, Zenarruzabeitia O, Borrego F. Identification and Functional Analysis of Human CD56neg NK Cells by Flow Cytometry. Star Protocols. 2020; 1(3): 100149-100149. DOI:10.1016/j.xpro.2020.100149.
Zenarruzabeitia O, Vitallé J, Terrén I, Orrantia A, Astigarraga I, Dopazo L, et al. CD300c costimulates IgE-mediated basophil activation, and its expression is increased in patients with cow's milk allergy. J Allergy Clin Immunol. 2019; 143(2): 700-7115. DOI:10.1016/j.jaci.2018.05.022.
Prieto Fernandez E, Maria Aransay A, Royo F, Gonzalez E, Jose Lozano J, Santos Zorrozua B, et al. A Comprehensive Study of Vesicular and Non-Vesicular miRNAs from a Volume of Cerebrospinal Fluid Compatible with Clinical Practice. Theranostics. 2019; 9(16): 4567-4579. DOI:10.7150/thno.31502.
Fernandez Cooke E, Barrios Tascon A, Sanchez Manubens J, Anton J, Grasa Lozano CD, Aracil Santos J, et al. Epidemiological and clinical features of Kawasaki disease in Spain over 5 years and risk factors for aneurysm development. (2011-2016): KAWA-RACE study group. PLoS One. 2019; 14(5). DOI:10.1371/journal.pone.0215665.
Vitallé J, Terrén I, Orrantia A, Pérez Garay R, Vidal F, Iribarren JA, et al. CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients. Cell Mol Immunol. 2019; 16(12): 940-942. DOI:10.1038/s41423-019-0275-4.
Vitalle J, Carlon Andres I, Zenarruzabeitia O, Padilla Parra S, Borrego F. CD300a receptor promotes HIV-cell fusion through the interaction with phosphatidylserine and phosphatidylethanolamine. EUR BIOPHYS J BIOPHY. 2019; 48(1): 248-248
Auduge N, Padilla Parra S, Tramier M, Borghi N, Coppey Moisan M. Chromatin condensation fluctuations rather than steady-state predict chromatin accessibility. Nucleic Acids Res. 2019; 47(12): 6184-6194. DOI:10.1093/nar/gkz373.
Coomer CA, Iliopoulou M, Dustin ML, Compeer EB, Compton AA, Padilla Parra S. Single-cell resolution of metabolic control over HIV-1 entry and a role for membrane lipid order and tension. EUR BIOPHYS J BIOPHY. 2019; 48(1): 244-244
Shaikh F, Zhao Y, Alvarez L, Iliopoulou M, Lohans C, Schofield CJ, et al. Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library. J Med Chem. 2019; 62(6): 2928-2937. DOI:10.1021/acs.jmedchem.8b01328.
Vitalle J, Terren I, Orrantia A, Zenarruzabeitia O, Borrego F. CD300 receptor family in viral infections. Eur J Immunol. 2019; 49(3): 364-374. DOI:10.1002/eji.201847951.
Anzilotti C, Swan DJ, Boisson B, Deobagkar Lele M, Oliveira C, Chabosseau P, et al. An essential role for the Zn2+ transporter ZIP7 in B cell development. NAT IMMUNOL. 2019; 20(3): 350-350. DOI:10.1038/s41590-018-0295-8.
Astigarraga I, Garcia Obregon S, Alba Pavon P, Seijas I, Pilar Orive J, Borrego F, et al. THE ROLE IN DIAGNOSIS OF HIGH SERUM LEVELS OF sCD25 AND sCD163 IN PATIENTS WITH SEVERE SEPSIS AND HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH). Pediatr Blood Cancer. 2019; 66(1): 1-1
Vanaclocha Espi M, Ibanez J, Molina Barcelo A, Jose Valverde Roig M, Perez E, Nolasco A, et al. Risk factors for severe complications of colonoscopy in screening programs. Prev Med. 2019; 118: 304-308. DOI:10.1016/j.ypmed.2018.11.010.
Martorell Calatayud C, Carnes J, Michavila Gomez A, Dopazo Fernandez L, Echeverria Zudaire L, Santana Rodriguez C, et al. Oral Immunotherapy to Hake in 8 Pediatric Patients. J Invest Allergol Clin Immunol. 2019; 29(4): 294-294. DOI:10.18176/jiaci.0372.
Daniel Grasa C, Anton J, Crespo D, Garcia M, Lopez A, Lirola Cruz MJ, et al. Kawasaki disease in infants 3 months of age and younger: a multicentre Spanish study. Ann Rheum Dis. 2019; 78(2): 289-290. DOI:10.1136/annrheumdis-2018-213891.
Constantinides C, McNeill E, Carnicer R, Zen AH, Sainz Urruela R, Shaw A, et al. Improved cellular uptake of perfluorocarbon nanoparticles for in vivo murine cardiac F-19 MRS/MRI and temporal tracking of progenitor cells. Nanomedicine. 2019; 18: 391-401. DOI:10.1016/j.nano.2018.10.014.
Jauregui I, Sanchez J, Segurola A, Galan C, Seras Y, Gamboa PM. Allergic contact dermatitis by isobornyl acrylate in glucose monitoring devices: Report of two cases. Contact Dermatitis. 2019; 81(3): 219-220. DOI:10.1111/cod.13349.
Terren I, Orrantia A, Vitalle J, Zenarruzabeitia O, Borrego F. NK Cell Metabolism and Tumor Microenvironment. Front Immunol. 2019; 10: 2278-2278. DOI:10.3389/fimmu.2019.02278.
Vitalle J, Terren I, Orrantia A, Segurola A, Seras Y, Gamboa PM, et al. Increased expression levels of CD300c on basophils from allergic individuals. World Allergy Organ J. 2019; 12(9): 100060-100060. DOI:10.1016/j.waojou.2019.100060.
Gamboa PM, Sánchez J, Segurola A, Galán C, García Lirio E, Seras Y, et al. Occupational contact dermatitis due to rosewood in a Basque wind instrument (txistu). Contact Dermatitis. 2019; 81(6): 450-451. DOI:10.1111/cod.13357.
Terrén I, Orrantia A, Vitallé J, Zenarruzabeitia O, Borrego F. CFSE dilution to study human T and NK cell proliferation in vitro. Methods Enzymol. 2019; 631: 239-255. DOI:10.1016/bs.mie.2019.05.020.
Sanchez J, Segurola A, Seras Y, Martinez MD, Irazabal MB, Jauregui I, et al. Tolerance to Iopamidol in Iomeprol allergic patients. Allergy. 2019; 74: 860-861
Sanchez J, Segurola A, Seras Y, Gamboa PM, Martinez MD, Irazabal MB, et al. Cross reactivity to cephalosporins and carbapenems in penicillin allergic patients. Allergy. 2019; 74: 860-860
Shaikh F, Zhao Y, Alvarez L, Iliopoulou M, Lohans C, Schofield CJ, et al. Structure-Based in Silico Screening Identifies a Potent Ebolavirus Inhibitor from a Traditional Chinese Medicine Library (vol 62, pg 2928, 2019). J Med Chem. 2019; 62(21): 10004-10004. DOI:10.1021/acs.jmedchem.9b01711.
Iliopoulou M, Nolan R, Alvarez L, Watanabe Y, Coomer CA, Jakobsdottir GM, et al. A dynamic three-step mechanism drives the HIV-1 pre-fusion reaction (vol 25, pg 814, 2018). Nat Struct Mol Biol. 2019; 26(6): 526-526. DOI:10.1038/s41594-019-0244-8.
Garcia Obregon S, Azkargorta M, Seijas I, Pilar Orive J, Borrego F, Elortza F, et al. Identification of a panel of serum protein markers in early stage of sepsis and its validation in a cohort of patients. J Microbiol Immunol Infect. 2018; 51(4): 465-472. DOI:10.1016/j.jmii.2016.12.002.
Gamboa PM, Bartolomé B, García Lirio E, Cuesta Herranz J, Pastor Vargas C. Aldolase A new Crustacea allergen. Ann Allergy Asthma Immunol. 2018; 121(2): 246-247. DOI:10.1016/j.anai.2018.04.025.
Gomez Fernandez P, Urtasun A, Paton AW, Paton JC, Borrego F, Dersh D, et al. Long Interleukin-22 Binding Protein Isoform-1 Is an Intracellular Activator of the Unfolded Protein Response. Front Immunol. 2018; 9: 2934-2934. DOI:10.3389/fimmu.2018.02934.
Nolan R, Alvarez LA, Griffiths SC, Elegheert J, Siebold C, Padilla Parra S. Calibration-free In Vitro Quantification of Protein Homo-oligomerization Using Commercial Instrumentation and Free, Open Source Brightness Analysis Software. J Vis Exp. 2018. DOI:10.3791/58157.
Terren I, Mikelez I, Odriozola I, Gredilla A, Gonzalez J, Orrantia A, et al. Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells. Front Immunol. 2018; 9. DOI:10.3389/fimmu.2018.00737.
Vitalle J, Terren I, Gamboa Urquijo L, Orrantia A, Tarancon Diez L, Genebat M, et al. Altered expression of CD300a inhibitory receptor on CD4+ T cells from human immunodeficiency virus-1-infected patients: Association with disease progression markers. Front Immunol. 2018; 9. DOI:10.3389/fimmu.2018.01709.
Iliopoulou M, Nolan R, Alvarez L, Watanabe Y, Coomer CA, Jakobsdottir GM, et al. A dynamic three-step mechanism drives the HIV-1 pre-fusion reaction. Nat Struct Mol Biol. 2018; 25(9): 814-814. DOI:10.1038/s41594-018-0113-x.
Zenarruzabeitia O, Vitallé J, Astigarraga I, Borrego F. Natural Killer Cells to the Attack: Combination Therapy against Neuroblastoma. Clin Cancer Res. 2017; 23(3): 615-617. DOI:10.1158/1078-0432.CCR-16-2478.
Vitalle J, Zenarruzabeitia O, Terren I, Plana M, Guardo AC, Leal L, et al. Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression. Front Immunol. 2017; 8: 836-836. DOI:10.3389/fimmu.2017.00836.
Herrera L, Salcedo JM, Santos S, Vesga MA, Borrego F, Eguizabal C. OP9 Feeder Cells Are Superior to M2-10B4 Cells for the Generation of Mature and Functional Natural Killer Cells from Umbilical Cord Hematopoietic Progenitors. Front Immunol. 2017; 8: 755-755. DOI:10.3389/fimmu.2017.00755.
Zenarruzabeitia O, Vitalle J, Garcia Obregon S, Astigarraga I, Eguizabal C, Santos S, et al. The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults. Sci Rep. 2016; 6: 32693-32693. DOI:10.1038/srep32693.
Borrego F, Larrucea S, Solana R, Tarazona R. Editorial: NK Cell-Based Cancer immunotherapy. Front Immunol. 2016; 7: 249-249. DOI:10.3389/fimmu.2016.00249.
Li H, Borrego F, Nagata S, Tolnay M. Fc Receptor-like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue-like Memory B Cells. J Immunol. 2016; 196(10): 4064-4074. DOI:10.4049/jimmunol.1501027.
Dimitrova M, Zenarruzabeitia O, Borrego F, Simhadri VR. CD300c is uniquely expressed on CD56(bright) Natural Killer Cells and differs from CD300a upon ligand recognition. Sci Rep. 2016; 6: 23942-23942. DOI:10.1038/srep23942.
Garcia Obregon S, Seijas I, Pilar Orive J, Ruano C, Pena A, Zenarruzabeitia O, et al. High Levels of sCD25 and sCD163 in Patients Diagnosed with Sepsis. Could They be Useful for Sepsis Diagnosis and Differential Diagnosis with Hemophagocytic Lymphohistiocytosis (HLH)?. Pediatr Blood Cancer. 2016; 63(2): 42-42
Eguizabal C, Zenarruzabeitia O, Monge J, Santos S, Vesga MA, Maruri N, et al. Natural killer cells for cancer immunotherapy: pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Front Immunol. 2015; 5: 439-439. DOI:10.3389/fimmu.2014.00439.
Zenarruzabeitia O, Vitalle J, Eguizabal C, Simhadri VR, Borrego F. The Biology and Disease Relevance of CD300a, an Inhibitory Receptor for Phosphatidylserine and Phosphatidylethanolamine. J Immunol. 2015; 194(11): 5053-5060. DOI:10.4049/jimmunol.1500304.
Simhadri VR, Dimitrova M, Mariano JL, Zenarruzabeitia O, Zhong W, Ozawa T, et al. A Human Anti-M2 Antibody Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Cytokine Secretion by Resting and Cytokine-Preactivated Natural Killer (NK) Cells. PLoS One. 2015; 10(4). DOI:10.1371/journal.pone.0124677.
Iglesias Ara A, Zenarruzabeitia O, Buelta L, Merino J, Zubiaga AM. E2F1 and E2F2 prevent replicative stress and subsequent p53-dependent organ involution. Cell Death Differ. 2015; 22(10): 1577-1589. DOI:10.1038/cdd.2015.4.
Simhadri VR, Mariano JL, Zenarruzabeitia O, Seroogy CM, Holland SM, Kuehn HS, et al. Intact IL-12 signaling is necessary for the generation of human natural killer cells with enhanced effector function after restimulation. J Allergy Clin Immunol. 2014; 134(5): 1190-1193. DOI:10.1016/j.jaci.2014.06.006.
Amo L, Tamayo Orbegozo E, Maruri N, Eguizabal C, Zenarruzabeitia O, Riñón M, et al. Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. Front Oncol. 2014; 4(SEP): 245-245. DOI:10.3389/fonc.2014.00245.
Peruzzi G, Femnou L, Gil-Krzewska A, Borrego F, Weck J, Krzewski K, Coligan JE. Membrane-Type 6 Matrix Metalloproteinase Regulates the Activation-Induced Downmodulation of CD16 in Human Primary NK Cells. J Immunol.2013;191:1883-94. FI: 5,520(Q1)
Tesis del grupo
Autor/a: Iñigo Terrén Martínez. Título: Human IL-12/15/18-stimulated natural killer cells: phenotypic, metabolic and functional features. Directores/as: Francisco Borrego Rabasco, Olatz Zenarruzabeitia Belaustegi. URL: http://hdl.handle.net/10810/59594.
Autor/a: Ane Orrantia Robles. Título: Natural killer cell subset reconstitution after autologous hematopoietic stem cell transplantation in multiplemyeloma patients. Directores/as: Dr. Francisco Borrego Rabasco, Dra. Olatz Zenarruzabeitia Belaustegi. URL: http://hdl.handle.net/10810/56147.
Autor/a: Joana Vitallé Andrade. Título: "Human CD300 receptors expression, regulation and function in the immune system. Implication in human immunodeficiency virus type 1 infection". Directores/as: Dr. Francisco Borrego Rabasco, Dra. Olatz Zenarruzabeitia Belaustegi.
